Curated News
By: NewsRamp Editorial Staff
September 10, 2024
Aclarion Completes Nociscan Exams for Initial LIFEHAB Enrolled Patients in Norway Trial
Discuss on Reddit
Substack
Telegram
GithubTLDR
- Aclarion's Nociscan technology provides an advantage in identifying chronic low back pain biomarkers for treatment response.
- Nociscan uses Magnetic Resonance Spectroscopy to quantify biomarkers and proprietary algorithms to determine the source of pain.
- Nociscan's potential to help physicians identify optimal treatment options could improve patient outcomes and reduce chronic low back pain.
- Aclarion's Nociscan technology is an innovative approach using magnetic resonance spectroscopy for noninvasive disc pain evaluation.
Impact - Why it Matters
This news matters as it signifies progress in utilizing advanced technology to improve the diagnosis and treatment of chronic low back pain. The results of the LIFEHAB trial, along with other evidence, could pave the way for successful reimbursement in healthcare systems, potentially impacting future treatment options for patients with chronic low back pain.
Summary
Aclarion, Inc., a healthcare technology company, has completed the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. The trial compares treatment outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation, utilizing Nociscan to evaluate how biomarkers in the discs of the lumbar spine correspond with treatment response. This marks a significant step in leveraging biomarkers and augmented intelligence algorithms to help physicians identify the location of chronic low back pain.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Aclarion Completes Nociscan Exams for Initial LIFEHAB Enrolled Patients in Norway Trial
